KYOWA KIRIN CO. LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,656 JPY | +2.87% |
|
+2.53% | +12.05% |
| May. 07 | Kyowa Kirin's Profit Up 15% in Q1 | MT |
| May. 06 | Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April | MT |
| Sales 2024 * | 473B 3.01B | Sales 2025 * | 485B 3.08B | Capitalization | 1,415B 8.99B |
|---|---|---|---|---|---|
| Net income 2024 * | 66.65B 423M | Net income 2025 * | 72.49B 461M | EV / Sales 2024 * | 2.3 x |
| Net cash position 2024 * | 328B 2.08B | Net cash position 2025 * | 360B 2.29B | EV / Sales 2025 * | 2.18 x |
| P/E ratio 2024 * |
21.1
x | P/E ratio 2025 * |
19.4
x | Employees | 5,974 |
| Yield 2024 * |
2.21% | Yield 2025 * |
2.31% | Free-Float | 45.89% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.87% | ||
| 1 week | +2.53% | ||
| Current month | +0.25% | ||
| 1 month | +0.25% | ||
| 3 months | -10.06% | ||
| 6 months | +8.97% | ||
| Current year | +12.05% |
1 week
2 536.00
2 655.50
1 month
2 536.002 716.00
Current year
2 266.503 009.00
1 year
2 266.503 009.00
3 years
2 266.504 240.00
5 years
1 674.004 240.00
10 years
1 094.004 240.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 86-03-31 | |
Masashi Miyamoto
PSD | President | 64 | 85-03-31 |
| Chief Tech/Sci/R&D Officer | 62 | 10-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Oyamada
BRD | Director/Board Member | 68 | 21-02-28 |
Yoshihisa Suzuki
BRD | Director/Board Member | 69 | 22-02-28 |
| Director/Board Member | 66 | 08-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.22% | 19 M€ | +11.22% | ||
| 0.44% | 10 M€ | +15.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2,656 | +2.87% | 4,286,700 |
| 24-05-30 | 2,582 | +0.88% | 866,600 |
| 24-05-29 | 2,559 | -0.62% | 1,053,900 |
| 24-05-28 | 2,575 | -0.31% | 966,300 |
| 24-05-27 | 2,583 | +0.58% | 829,500 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,656
JPY
Average target price
3,054
JPY
Spread / Average Target
+15.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.05% | 8.78B | |
| +15.54% | 77.63B | |
| +58.17% | 4.93B | |
| -14.94% | 4.79B | |
| -.--% | 3.8B | |
| +21.94% | 2.46B | |
| -26.63% | 2.2B | |
| +16.75% | 2.1B | |
| -37.97% | 1.96B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 4151 Stock
